VIOLIN Logo
Cov19VaxKB Banner
Search: for Help
Home
Introduction
Statistics
Authorized Vaccines
Phase III Vaccines
Phase II Vaccines
Phase I Vaccines
Preclinical Vaccines
Vaccine Safety
Vaccine Design
Literature Search
News
Data Submission
Data Exchange
Data Download
Tutorial
Links
Documentation
Updates
Acknowledgements
FAQs
Disclaimer
Contact Us
UMMS Logo

Vaxlert: Peer-reviewed Vaccine Publications in Current Month

From Dec 01, 2024 To Dec 04, 2024:

SARS-CoV-2 (COVID-19)

  1. Georgakopoulou VE, Taskou C, Spandidos DA, Sarantaki A. Long COVID‑19 and pregnancy: A systematic review Biomedical reports 22(1):15 2025 [PMID: 39624781]
  2. Ørbo HS, de Matos Kasahara T, Wolf AS, Bjørlykke KH, Sexton J, Jyssum I, Tveter AT, Solum G, Kjønstad IF, Bhandari S, Christensen IE, Kvien TK, Lind A, Kared H, Jahnsen J, Haavardsholm EA, Munthe LA, Provan SA, Vaage JT, Mjaaland S, Syversen SW, Jørgensen KK, Grødeland G, Goll GL. Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study The Lancet regional health. Europe 48:101121 2025 [PMID: 39624496]
  3. Alghalyini B, Zia Zaidi AR, Zangiabadi S, Alamgir A, Tamim H. Vaccine hesitancy among Syrian refugee parents in Canada: A multifaceted challenge in public health Human vaccines & immunotherapeutics 20(1):2430086 2024 [PMID: 39618040]
  4. Hussein MF, Ibrahim SA, Abdel-Rahman S, Elshabrawy A, Nasr HAA, Yazbek S, Jabbar A, Albadri CT, Alsanafi M, Aji N, Youssef N, Hammad HM, Abdullah FSA, Elrewany E, Tahoun MM, Tolba M, Abo Salama MK, Ghazy RM. Psychological antecedents of vaccine inequity: keys to improve the rates of vaccination The Journal of the Egyptian Public Health Association 99(1):31 2024 [PMID: 39627491]
  5. Lv T, Chen J, Li H, Chen X, Zhang N, Ma C, Zhang Y, You P. Influenza A virus continues to circulate among children in Linyi, northern China, after the relaxation of COVID-19 control measures Scientific reports 14(1):30164 2024 [PMID: 39627283]
  6. Joaquin-Damas E, Mamelund SE, Schnneider BM, Sánchez-Hernández BE, Patishtán-López A, Bleichrodt A, Chowell G. Evaluating COVID-19 impact, vaccination, birth registration, and underreporting in a predominantly indigenous population in Chiapas, Mexico BMC infectious diseases 24(1):1376 2024 [PMID: 39627719]
  7. Kostandova N, Schluth C, Arambepola R, Atuhaire F, Bérubé S, Chin T, Cleary E, Cortes-Azuero O, García-Carreras B, Grantz KH, Hitchings MDT, Huang AT, Kishore N, Lai S, Larsen SL, Loisate S, Martinez P, Meredith HR, Purbey R, Ramiadantsoa T, Read J, Rice BL, Rosman L, Ruktanonchai N, Salje H, Schaber KL, Tatem AJ, Wang J, Cummings DAT, Wesolowski A. A systematic review of using population-level human mobility data to understand SARS-CoV-2 transmission Nature communications 15(1):10504 2024 [PMID: 39627231]
  8. Jagomast T, Finck J, Tangemann-Münstedt I, Auth K, Drömann D, Franzen KF. Google Trends Assessment of Keywords Related to Smoking and Smoking Cessation During the COVID-19 Pandemic in 4 European Countries: Retrospective Analysis Online journal of public health informatics 16:e57718 2024 [PMID: 39626237]
  9. Hurst JR, Naghibosadat M, Budowski P, Liu J, Samaan P, Budiman F, Kurtesi A, Qi F, Menon H, Krishnan R, Abioye J, Gingras AC, Ostrowski M, Orozco NM, Kozak RA. Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice PloS one 19(12):e0314061 2024 [PMID: 39625929]
  10. Blondeau JM. Long COVID: a consequence of chronic post-infectious inflammation! Expert review of respiratory medicine 2024 [PMID: 39625700]
  11. Infante-Domínguez C, Salto-Alejandre S, Álvarez-Marín R, Sabé N, Ramos-Martínez A, Moreno A, Ferreira de Moraes K, Palacios-Baena ZR, Muñoz P, Fernández-Ruiz M, Blanes M, Fariñas C, Vidal E, Merino de Lucas E, Halpern M, Hernández-Gallego R, Bassetti M, Mularoni A, Gutiérrez-Dalmau A, Rinaldi M, Jiménez-Jorge S, Bodro M, Aranha-Camargo LF, Valerio M, Sánchez-Céspedes J, Gutiérrez-Gutiérrez B, Giannella M, Rodríguez-Baño J, Pachón J, Cordero E. COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study Scientific reports 14(1):30021 2024 [PMID: 39622951]
  12. Shen Y, Penrose K, Robertson M, Piltch-Loeb R, Fleary S, Kulkarni S, Teasdale C, Balasubramanian S, Yadav S, Chan BXJ, Sanborn J, Sahr JN, Srivastava A, Nash D, Parcesepe A. Persistence of anxiety and depression symptoms and their impact on the COVID-19 vaccine uptake Epidemiology and psychiatric sciences 33:e74 2024 [PMID: 39622768]
  13. Vassilopoulos S, Mylonakis E. After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y Annals of internal medicine 2024 [PMID: 39622055]
  14. Rayguru C, Husnayain A, Chiu HS, Sumazin P, Su EC. Predictive analysis of COVID-19 occurrence and vaccination impacts across the 50 US states Computers in biology and medicine 185:109493 2024 [PMID: 39626459]
  15. Chen R, Gilbert NL, Dubé È. Adult influenza vaccination coverage before, during and after the COVID-19 pandemic in Canada BMC public health 24(1):3357 2024 [PMID: 39623359]
  16. Zhu R, Zhao Y, Yin H, Shu L, Ma Y, Tao Y. Identification of immune-related hub genes and potential molecular mechanisms involved in COVID-19 via integrated bioinformatics analysis Scientific reports 14(1):29964 2024 [PMID: 39622956]
  17. Faliti CE, Van TTP, Anam FA, Cheedarla N, Williams ME, Mishra AK, Usman SY, Woodruff MC, Kraker G, Runnstrom MC, Kyu S, Sanz D, Ahmed H, Ghimire M, Morrison-Porter A, Quehl H, Haddad NS, Chen W, Cheedarla S, Neish AS, Roback JD, Antia R, Hom J, Tipton CM, Lindner JM, Ghosn E, Khurana S, Scharer CD, Khosroshahi A, Lee FE, Sanz I. Publisher Correction: Disease-associated B cells and immune endotypes shape adaptive immune responses to SARS-CoV-2 mRNA vaccination in human SLE Nature immunology 2024 [PMID: 39622950]
  18. Dong Z, Chen Y, Li C, Tricco TS, Hu T. Integrating graph and reinforcement learning for vaccination strategies in complex networks Scientific reports 14(1):29923 2024 [PMID: 39622907]
  19. Pan D, Martin CA, Nazareth J, Sze S, Al-Oraibi A, Gogoi M, Grolmusova N, Divall P, Decker J, Fletcher E, Williams C, Hay J, Baggaley RF, Wyllie AL, Stephenson I, Gaillard E, Nellums LB, Clark TW, Van-Tam JN, Cowling BJ, Hollingsworth TD, Gray L, Barer M, Pareek M. Defining within-host SARS-CoV-2 RNA viral load kinetics during acute COVID-19 infection within different respiratory compartments and their respective associations with host infectiousness: a protocol for a systematic review and meta-analysis BMJ open 14(12):e085127 2024 [PMID: 39622563]
  20. Jeong J, Jo H, Park J, Smith L, Rahmati M, Lee K, Ha Y, Yon DK. Global estimates of vaccine-associated hepatic autoimmune disorders and their related vaccines, 1968-2024: An international analysis of the WHO pharmacovigilance database International archives of allergy and immunology :1-15 2024 [PMID: 39622209]
  21. Tsugawa Y, Furukawa K, Ise T, Takayama M, Ota T, Kuroda T, Shano S, Hashimoto T, Konishi H, Ishihara T, Sato M, Kamada H, Fukao K, Shishido T, Yoshikawa M, Takahashi T, Nagata S. Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo PloS one 19(12):e0300297 2024 [PMID: 39621673]
  22. Weirauch T, Schüttfort G, Vehreschild MJGT. Syncopes, paresis and loss of vision after COVID-19 mRNA-based vaccination and SARS-CoV-2 infection Infection 2024 [PMID: 39621236]
  23. Leone JP, Leone J, Hassett MJ, Freedman RA, Avila J, Vallejo CT, Tayob N, Tolaney SM, Lin NU. Incidence, treatment patterns, and mortality for patients with breast cancer during the first year of the COVID-19 pandemic: a population-based study Breast cancer research and treatment 2024 [PMID: 39621161]
  24. Park C, Zabala PV. COVID-19 vaccine or booster uptake and hesitancy for children aged 6 months-5 years in the United States: A national descriptive study using the household pulse survey between March and May 2023 Vaccine: X 21:100582 2024 [PMID: 39624679]
  25. Maltezou HC, Gamaletsou MN, Chini M, Petrakis V, Rapti V, Giannouchos TV, Karantoni E, Kounouklas K, Stamou P, Karapanou Α, Basoulis D, Verykokkou AC, Souliotis K, Panagopoulos P, Hatzigeorgiou D, Poulakou G, Syrigos KN, Sipsas NV. Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece Infectious medicine 3(4):100144 2024 [PMID: 39624059]
  26. Son S, Jin S, Hong JY, Shin JM, Jung KE, Seo YJ, Kim CD, Hong D, Lee Y. Clinical Manifestation of Alopecia Areata After COVID-19 Infection or Vaccination Annals of dermatology 36(6):361-366 2024 [PMID: 39623612]
  27. Waghela H, Anvari S. T Cell Responses to SARS-CoV-2 Infection and Vaccination Are Elevated in B Cell Deficiency and Reduce Risk of Severe COVID-19 Pediatrics 154(Suppl 4):S59 2024 [PMID: 39620812]
  28. Williams KW. COVID-19 Vaccination in Patients With Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: A USIDNET Report Pediatrics 154(Suppl 4):S59-S60 2024 [PMID: 39620744]
  29. Seidu AA, Ampomah IG, Emeto TI. COVID-19 Vaccine Uptake and Associated Factors Among Persons With Disabilities in Ghana's Ashanti Region Health science reports 7(12):e70210 2024 [PMID: 39619081]
  30. Piché-Renaud PP, Drover SSM, Austin PC, Morris SK, Buchan SA, Nasreen S, Schwartz KL, Tadrous M, Thampi N, Wilson SE, Wilson K, Guttmann A, Kwong JC. COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study Vaccine :126539 2024 [PMID: 39617675]
  31. Classen JM, Muzalyova A, Römmele C, Nagl S, Ebigbo A, Schnoy E. Antibody response to SARS-CoV2 before and after the third vaccination in patients with Inflammatory Bowel Disease Digestive diseases (Basel, Switzerland) :1-19 2024 [PMID: 39616993]
  32. Schwab J, Foglierini M, Pescosolido E, Pacheco I, Ruiz Buendía GA, Madelon N, Pellaton C, Banderet V, Ribi C, Bergmann MM, Didierlaurent AM, Fenwick C, Duperrex O, Muller YD. Features of chronic urticaria after COVID-19 mRNA vaccine over time Communications medicine 4(1):254 2024 [PMID: 39616213]
  33. Denney MR, Moore K, Patterson B, Bialostozky A, Williams E. Mobile Flu Fighter! Development and Pilot Implementation of a Mobile Vaccination Program to Reduce Pediatric Influenza Vaccination Disparities Clinical pediatrics :99228241301848 2024 [PMID: 39614730]
  34. Tian S, Chen Y, Su Q, Sun B, Lin Z, Long Y, Wang H, Liao C, Zhang Y, Zheng J, Chen L, Guan S, Wang S, Xu X, Ai J, Zhang W, Deng J. Pertussis clinical profile shift, severity, prediction in a tertiary hospital: A comparative study before, during, and after COVID-19 in Southern China Journal of infection and public health 18(1):102610 2024 [PMID: 39626401]
  35. Hsieh MW, Lai CS, Chang YP, Lai YW. Surgical Treatment of Synkinetic Eyelid Closure in Marin-amat Syndrome Complicated by Facial Palsy After COVID-19 Vaccination The Journal of craniofacial surgery 2024 [PMID: 39620969]
  36. Yahaba M, Asano H, Saito K, Murata S, Kawasaki K, Chiba H, Yokota S, Yoshikawa H, Herai Y, Yamagishi K, Shiko Y, Matsushita K, Hanaoka H, Taniguchi T, Yokote K, Nakajima H, Ido E, Igari H. Antibody Responses and Infection Prevention following the Sixth Vaccination using the BA.1 bivalent COVID-19 vaccine among Healthcare workers during the XBB variant Dominance in Japan Japanese journal of infectious diseases 2024 [PMID: 39617483]
  37. Aso S, Ono S, Michihata N, Uemura K, Yasunaga H. Differences in patient characteristics, treatments, and mortality of COVID-19 between 2022 and 2020-2021 Japanese journal of infectious diseases 2024 [PMID: 39617481]
  38. Cosma C, Radi A, Cattano R, Zanobini P, Bonaccorsi G, Lorini C, Del Riccio M. Exploring Chatbot contributions to enhancing vaccine literacy and uptake: A scoping review of the literature Vaccine 44:126559 2024 [PMID: 39615346]
  39. Flores D, Luna EM. The effectiveness of vaccines against COVID-19 in Mexico: A time series approach Vaccine 44:126565 2024 [PMID: 39615344]
  40. Thiem VD, Anh DD, Ha VH, Van Thom N, Thang TC, Mateus J, Carreño JM, Raghunandan R, Huong NM, Mercer LD, Flores J, Escarrega EA, Raskin A, Thai DH, Van Be L, Sette A, Innis BL, Krammer F, Weiskopf D. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial Vaccine 44:126542 2024 [PMID: 39615342]
  41. Arai T, Inoue Y, Akasaka K, Masunaga A, Fujita M, Yamaguchi E, Saigusa M, Murakami K, Kurahara Y, Tsuyuguchi K, Suzuki T, Miyazaki Y, Bando M, Suda T. Severity and prognosis of COVID-19 complicated by autoimmune pulmonary alveolar proteinosis Respiratory investigation 63(1):20-26 2024 [PMID: 39615320]
  42. Forero-Peña DA, Carrión-Nessi FS, Omaña-Ávila ÓD, Mendoza-Millán DL, Moncada-Ortega A, Landaeta ME. COVID-19 in Venezuela: Costs and challenges of management severe cases at home in a crisis setting Archives of medical research 56(3):103126 2024 [PMID: 39615145]
  43. Syed AA, Eqbal F, Shamsi HR, Syed ARS, Zakir SJ, Fawzy M, Khan KS. Comparative effectiveness of three common SARS-COV-2 vaccines: A network meta-analysis of randomized trials Semergen 51(2):102343 2024 [PMID: 39615116]
  44. El Kalach RR, Jones-Jack NH, Grabenstein JD, Elam M, Olorukooba A, deMartino AK, Vazquez M, Stokley S, Meyer SA, Wang TW, Himsel A, Medernach C, Jenkins K, Marovich S, Bradley MD, Manns BJ, Romerhausen D, Moore LB. Pharmacists' Answer to the COVID-19 Pandemic: Contribution of the Federal Retail Pharmacy Program to COVID-19 Vaccination Across Sociodemographic Characteristics- United States Journal of the American Pharmacists Association : JAPhA :102305 2024 [PMID: 39615591]
  45. Penglin Y, Guangsen L. Re: Shukla et al.: The risk of optic neuritis following mRNA Coronavirus disease 2019 vaccination compared to Coronavirus disease 2019 infection and other vaccinations. (Ophthalmology. 2024;131:1076-1082) Ophthalmology 2024 [PMID: 39614849]
  46. Rong Z, Mai H, Ebert G, Kapoor S, Puelles VG, Czogalla J, Hu S, Su J, Prtvar D, Singh I, Schädler J, Delbridge C, Steinke H, Frenzel H, Schmidt K, Braun C, Bruch G, Ruf V, Ali M, Sühs KW, Nemati M, Hopfner F, Ulukaya S, Jeridi D, Mistretta D, Caliskan ÖS, Wettengel JM, Cherif F, Kolabas ZI, Molbay M, Horvath I, Zhao S, Krahmer N, Yildirim AÖ, Ussar S, Herms J, Huber TB, Tahirovic S, Schwarzmaier SM, Plesnila N, Höglinger G, Ondruschka B, Bechmann I, Protzer U, Elsner M, Bhatia HS, Hellal F, Ertürk A. Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19 Cell host & microbe 2024 [PMID: 39615487]
  47. Ismaila MS, Lall KR, Sookram K, Sundaram V, Jones KR. Conventional and Nonconventional Therapies for COVID-19 Management in Trinidad Scientifica 2024:1545153 2024 [PMID: 39618689]
  48. Niu M, Mu Y, Adriko M, Candia R, Jones MK, McManus DP, Egwang TG, Cai P. COVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort from Schistosoma mansoni-endemic villages in Mayuge District, Uganda: a cross-sectional study Frontiers in public health 12:1437063 2024 [PMID: 39624416]
  49. González Rodríguez JL, Oprescu AM, Muñoz Lezcano S, Cordero Ramos J, Romero Cabrera JL, Armengol de la Hoz MÁ, Estella Á. Assessing the impact of vaccines on COVID-19 efficacy in survival rates: a survival analysis approach for clinical decision support Frontiers in public health 12:1437388 2024 [PMID: 39624415]
  50. Harris DC, Shanker A, Montoya MM, Llewellyn TR, Matuszak AR, Lohar A, Kubicek-Sutherland JZ, Li YW, Wilding K, Mcmahon B, Gnanakaran S, Ribeiro RM, Perelson AS, Molina-París C. Quantification of heterogeneity in human CD8(+) T cell responses to vaccine antigens: an HLA-guided perspective Frontiers in immunology 15:1420284 2024 [PMID: 39624092]
  51. Tian T, Zhang X, Zhang F, Huang X, Li M, Quan Z, Wang W, Lei J, Wang Y, Liu Y, Wang JH. Harnessing AI for advancing pathogenic microbiology: a bibliometric and topic modeling approach Frontiers in microbiology 15:1510139 2024 [PMID: 39624726]
  52. Isiaka SD, Samuel OW, Jimoh AU, Atobatele S, Sampson S, Daniel V, David JC, Odira Okoye I, Adegoke Z. Partnership coordination for optimized COVID-19 vaccination: a case study of Benue and Niger states Frontiers in public health 12:1466648 2024 [PMID: 39624406]
  53. Kang J, Park J, Jo H, Lee H, Lee K, Kim S, Kang J, Lee JH, Papadopoulos NG, Smith L, Shin JY, Rahmati M, Cho SH, Cho JK, Lee S, Pizzol D, Yeo SG, Lee H, Jin SP, Yon DK. Global Burden of Vaccine-Associated Chronic Urticaria, 2010-2023: From the Global Pharmacovigilance Database Allergy, asthma & immunology research 16(6):613-625 2024 [PMID: 39622686]
  54. Lu X, Gao L, Qian SJ, Dai LMJ, Zhou ZY, Qiu TL, Xia Y, Miao Y, Qin SC, Fan L, Xu W, Li JY, Zhu HY. [Single-center study of COVID-19 in patients with chronic lymphocytic leukemia] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 45(10):923-930 2024 [PMID: 39622756]
  55. Hernández Morales MDR, Aguirre Barbosa M, Mancilla Hernández E, González Hidalgo SA, Alavez López E, Maldonado Castañeda S. [Adverse events from the Pfizer-BioNTech® COVID-19vaccine in children 5-17 years old] Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 71(3):139-145 2024 [PMID: 39625796]
  56. Kumar Chattu V, Pushkaran A, Narayanan P. Political Prioritization of Access to Medicines and Right to Health: Need for an Effective Global Health Governance Through Global Health Diplomacy Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap" International journal of health policy and management 13:8578 2024 [PMID: 39620545]
  57. Gleeson D, Scheibner J, Tenni BF, Townsend B, Nicol D. Pandemic Agreement Must Include Levers to Redirect Pharmaceutical Industry Behaviour During Pandemics Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap" International journal of health policy and management 13:8589 2024 [PMID: 39620533]
  58. Uraki R. [Analysis of RNA virus pathogenicity and development of novel prevention methods.] Uirusu 74(1):57-66 2024 [PMID: 39617454]

See more by clicking HERE

Coronavirus

  1. Georgakopoulou VE, Taskou C, Spandidos DA, Sarantaki A. Long COVID‑19 and pregnancy: A systematic review Biomedical reports 22(1):15 2025 [PMID: 39624781]
  2. Alghalyini B, Zia Zaidi AR, Zangiabadi S, Alamgir A, Tamim H. Vaccine hesitancy among Syrian refugee parents in Canada: A multifaceted challenge in public health Human vaccines & immunotherapeutics 20(1):2430086 2024 [PMID: 39618040]
  3. Hussein MF, Ibrahim SA, Abdel-Rahman S, Elshabrawy A, Nasr HAA, Yazbek S, Jabbar A, Albadri CT, Alsanafi M, Aji N, Youssef N, Hammad HM, Abdullah FSA, Elrewany E, Tahoun MM, Tolba M, Abo Salama MK, Ghazy RM. Psychological antecedents of vaccine inequity: keys to improve the rates of vaccination The Journal of the Egyptian Public Health Association 99(1):31 2024 [PMID: 39627491]
  4. Lv T, Chen J, Li H, Chen X, Zhang N, Ma C, Zhang Y, You P. Influenza A virus continues to circulate among children in Linyi, northern China, after the relaxation of COVID-19 control measures Scientific reports 14(1):30164 2024 [PMID: 39627283]
  5. Kostandova N, Schluth C, Arambepola R, Atuhaire F, Bérubé S, Chin T, Cleary E, Cortes-Azuero O, García-Carreras B, Grantz KH, Hitchings MDT, Huang AT, Kishore N, Lai S, Larsen SL, Loisate S, Martinez P, Meredith HR, Purbey R, Ramiadantsoa T, Read J, Rice BL, Rosman L, Ruktanonchai N, Salje H, Schaber KL, Tatem AJ, Wang J, Cummings DAT, Wesolowski A. A systematic review of using population-level human mobility data to understand SARS-CoV-2 transmission Nature communications 15(1):10504 2024 [PMID: 39627231]
  6. Jagomast T, Finck J, Tangemann-Münstedt I, Auth K, Drömann D, Franzen KF. Google Trends Assessment of Keywords Related to Smoking and Smoking Cessation During the COVID-19 Pandemic in 4 European Countries: Retrospective Analysis Online journal of public health informatics 16:e57718 2024 [PMID: 39626237]
  7. Hurst JR, Naghibosadat M, Budowski P, Liu J, Samaan P, Budiman F, Kurtesi A, Qi F, Menon H, Krishnan R, Abioye J, Gingras AC, Ostrowski M, Orozco NM, Kozak RA. Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice PloS one 19(12):e0314061 2024 [PMID: 39625929]
  8. Infante-Domínguez C, Salto-Alejandre S, Álvarez-Marín R, Sabé N, Ramos-Martínez A, Moreno A, Ferreira de Moraes K, Palacios-Baena ZR, Muñoz P, Fernández-Ruiz M, Blanes M, Fariñas C, Vidal E, Merino de Lucas E, Halpern M, Hernández-Gallego R, Bassetti M, Mularoni A, Gutiérrez-Dalmau A, Rinaldi M, Jiménez-Jorge S, Bodro M, Aranha-Camargo LF, Valerio M, Sánchez-Céspedes J, Gutiérrez-Gutiérrez B, Giannella M, Rodríguez-Baño J, Pachón J, Cordero E. COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study Scientific reports 14(1):30021 2024 [PMID: 39622951]
  9. Shen Y, Penrose K, Robertson M, Piltch-Loeb R, Fleary S, Kulkarni S, Teasdale C, Balasubramanian S, Yadav S, Chan BXJ, Sanborn J, Sahr JN, Srivastava A, Nash D, Parcesepe A. Persistence of anxiety and depression symptoms and their impact on the COVID-19 vaccine uptake Epidemiology and psychiatric sciences 33:e74 2024 [PMID: 39622768]
  10. Zhu R, Zhao Y, Yin H, Shu L, Ma Y, Tao Y. Identification of immune-related hub genes and potential molecular mechanisms involved in COVID-19 via integrated bioinformatics analysis Scientific reports 14(1):29964 2024 [PMID: 39622956]
  11. Dong Z, Chen Y, Li C, Tricco TS, Hu T. Integrating graph and reinforcement learning for vaccination strategies in complex networks Scientific reports 14(1):29923 2024 [PMID: 39622907]
  12. Pan D, Martin CA, Nazareth J, Sze S, Al-Oraibi A, Gogoi M, Grolmusova N, Divall P, Decker J, Fletcher E, Williams C, Hay J, Baggaley RF, Wyllie AL, Stephenson I, Gaillard E, Nellums LB, Clark TW, Van-Tam JN, Cowling BJ, Hollingsworth TD, Gray L, Barer M, Pareek M. Defining within-host SARS-CoV-2 RNA viral load kinetics during acute COVID-19 infection within different respiratory compartments and their respective associations with host infectiousness: a protocol for a systematic review and meta-analysis BMJ open 14(12):e085127 2024 [PMID: 39622563]
  13. Tsugawa Y, Furukawa K, Ise T, Takayama M, Ota T, Kuroda T, Shano S, Hashimoto T, Konishi H, Ishihara T, Sato M, Kamada H, Fukao K, Shishido T, Yoshikawa M, Takahashi T, Nagata S. Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo PloS one 19(12):e0300297 2024 [PMID: 39621673]
  14. Maltezou HC, Gamaletsou MN, Chini M, Petrakis V, Rapti V, Giannouchos TV, Karantoni E, Kounouklas K, Stamou P, Karapanou Α, Basoulis D, Verykokkou AC, Souliotis K, Panagopoulos P, Hatzigeorgiou D, Poulakou G, Syrigos KN, Sipsas NV. Protection conferred by booster vaccine doses in hospitalized patients with COVID-19 during the SARS-CoV-2 Omicron BA.2 and BA.5 epidemics from 2022 to 2023 in Greece Infectious medicine 3(4):100144 2024 [PMID: 39624059]
  15. Son S, Jin S, Hong JY, Shin JM, Jung KE, Seo YJ, Kim CD, Hong D, Lee Y. Clinical Manifestation of Alopecia Areata After COVID-19 Infection or Vaccination Annals of dermatology 36(6):361-366 2024 [PMID: 39623612]
  16. Yahaba M, Asano H, Saito K, Murata S, Kawasaki K, Chiba H, Yokota S, Yoshikawa H, Herai Y, Yamagishi K, Shiko Y, Matsushita K, Hanaoka H, Taniguchi T, Yokote K, Nakajima H, Ido E, Igari H. Antibody Responses and Infection Prevention following the Sixth Vaccination using the BA.1 bivalent COVID-19 vaccine among Healthcare workers during the XBB variant Dominance in Japan Japanese journal of infectious diseases 2024 [PMID: 39617483]
  17. Aso S, Ono S, Michihata N, Uemura K, Yasunaga H. Differences in patient characteristics, treatments, and mortality of COVID-19 between 2022 and 2020-2021 Japanese journal of infectious diseases 2024 [PMID: 39617481]
  18. Thiem VD, Anh DD, Ha VH, Van Thom N, Thang TC, Mateus J, Carreño JM, Raghunandan R, Huong NM, Mercer LD, Flores J, Escarrega EA, Raskin A, Thai DH, Van Be L, Sette A, Innis BL, Krammer F, Weiskopf D. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial Vaccine 44:126542 2024 [PMID: 39615342]
  19. Arai T, Inoue Y, Akasaka K, Masunaga A, Fujita M, Yamaguchi E, Saigusa M, Murakami K, Kurahara Y, Tsuyuguchi K, Suzuki T, Miyazaki Y, Bando M, Suda T. Severity and prognosis of COVID-19 complicated by autoimmune pulmonary alveolar proteinosis Respiratory investigation 63(1):20-26 2024 [PMID: 39615320]
  20. Penglin Y, Guangsen L. Re: Shukla et al.: The risk of optic neuritis following mRNA Coronavirus disease 2019 vaccination compared to Coronavirus disease 2019 infection and other vaccinations. (Ophthalmology. 2024;131:1076-1082) Ophthalmology 2024 [PMID: 39614849]
  21. Niu M, Mu Y, Adriko M, Candia R, Jones MK, McManus DP, Egwang TG, Cai P. COVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort from Schistosoma mansoni-endemic villages in Mayuge District, Uganda: a cross-sectional study Frontiers in public health 12:1437063 2024 [PMID: 39624416]
  22. González Rodríguez JL, Oprescu AM, Muñoz Lezcano S, Cordero Ramos J, Romero Cabrera JL, Armengol de la Hoz MÁ, Estella Á. Assessing the impact of vaccines on COVID-19 efficacy in survival rates: a survival analysis approach for clinical decision support Frontiers in public health 12:1437388 2024 [PMID: 39624415]
  23. Harris DC, Shanker A, Montoya MM, Llewellyn TR, Matuszak AR, Lohar A, Kubicek-Sutherland JZ, Li YW, Wilding K, Mcmahon B, Gnanakaran S, Ribeiro RM, Perelson AS, Molina-París C. Quantification of heterogeneity in human CD8(+) T cell responses to vaccine antigens: an HLA-guided perspective Frontiers in immunology 15:1420284 2024 [PMID: 39624092]
  24. Isiaka SD, Samuel OW, Jimoh AU, Atobatele S, Sampson S, Daniel V, David JC, Odira Okoye I, Adegoke Z. Partnership coordination for optimized COVID-19 vaccination: a case study of Benue and Niger states Frontiers in public health 12:1466648 2024 [PMID: 39624406]
  25. Kang J, Park J, Jo H, Lee H, Lee K, Kim S, Kang J, Lee JH, Papadopoulos NG, Smith L, Shin JY, Rahmati M, Cho SH, Cho JK, Lee S, Pizzol D, Yeo SG, Lee H, Jin SP, Yon DK. Global Burden of Vaccine-Associated Chronic Urticaria, 2010-2023: From the Global Pharmacovigilance Database Allergy, asthma & immunology research 16(6):613-625 2024 [PMID: 39622686]
  26. Lu X, Gao L, Qian SJ, Dai LMJ, Zhou ZY, Qiu TL, Xia Y, Miao Y, Qin SC, Fan L, Xu W, Li JY, Zhu HY. [Single-center study of COVID-19 in patients with chronic lymphocytic leukemia] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 45(10):923-930 2024 [PMID: 39622756]
  27. Kumar Chattu V, Pushkaran A, Narayanan P. Political Prioritization of Access to Medicines and Right to Health: Need for an Effective Global Health Governance Through Global Health Diplomacy Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap" International journal of health policy and management 13:8578 2024 [PMID: 39620545]
  28. Gleeson D, Scheibner J, Tenni BF, Townsend B, Nicol D. Pandemic Agreement Must Include Levers to Redirect Pharmaceutical Industry Behaviour During Pandemics Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap" International journal of health policy and management 13:8589 2024 [PMID: 39620533]
  29. Uraki R. [Analysis of RNA virus pathogenicity and development of novel prevention methods.] Uirusu 74(1):57-66 2024 [PMID: 39617454]

See more by clicking HERE

Click HERE to see the publications in the last month.